LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

AstraZeneca PLC ADR

Fermé

72.9 0.84

Résumé

Variation du prix de l'action

24h

Actuel

Min

72.29

Max

73.15

Chiffres clés

By Trading Economics

Revenu

1.7B

3.4B

Ventes

-1.3B

14B

P/E

Moyenne du Secteur

29.004

51.198

BPA

0.934

Rendement du dividende

2.15

Marge bénéficiaire

25.037

Employés

94,300

EBITDA

610M

5B

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+20.44% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

2.15%

2.40%

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

7.5B

224B

Ouverture précédente

72.06

Clôture précédente

72.9

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

AstraZeneca PLC ADR Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

12 mai 2025, 09:36 UTC

Principaux Mouvements du Marché

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

29 avr. 2025, 10:14 UTC

Résultats

Correction to AstraZeneca Update

29 avr. 2025, 09:15 UTC

Résultats

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China -- 2nd Update

29 avr. 2025, 08:12 UTC

Résultats

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China -- Update

29 avr. 2025, 06:32 UTC

Résultats

AstraZeneca Sales, Earnings Rise

24 mars 2025, 03:15 UTC

Principaux Mouvements du Marché

Harbour BioMed Shares Soar on News of AstraZeneca Collaboration

28 mai 2025, 18:09 UTC

Résultats

Heart Disease Could Be a Goner When These New -2-

28 mai 2025, 18:09 UTC

Résultats

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

20 mai 2025, 06:09 UTC

Acquisitions, Fusions, Rachats

AstraZeneca Completes Acquisition of EsoBiotec

12 mai 2025, 12:07 UTC

Market Talk

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12 mai 2025, 07:20 UTC

Market Talk

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

8 mai 2025, 15:20 UTC

Résultats

Trump Announces U.S.-U.K. Trade Deal. Most Tariffs Aren't Coming Down. -- Barrons.com

29 avr. 2025, 13:09 UTC

Market Talk
Résultats

AstraZeneca's Oncology Miss Doesn't Dent Positive Outlook -- Market Talk

29 avr. 2025, 08:04 UTC

Market Talk
Résultats

AstraZeneca's Results Provide a Mixed Picture -- Market Talk

29 avr. 2025, 06:05 UTC

Résultats

AstraZeneca 1Q Core EPS $2.49

29 avr. 2025, 06:04 UTC

Résultats

AstraZeneca 1Q Net Pft $2.92B

29 avr. 2025, 06:02 UTC

Résultats

AstraZeneca: Committed to Further Invest and Grow in the U.S.

29 avr. 2025, 06:00 UTC

Résultats

AstraZeneca 1Q Core EPS Consensus Was $2.27

29 avr. 2025, 06:00 UTC

Résultats

AstraZeneca 1Q Revenue Consensus Was $13.80B

29 avr. 2025, 06:00 UTC

Résultats

AstraZeneca Backs 2025 View

29 avr. 2025, 06:00 UTC

Résultats

AstraZeneca PLC 1Q EPS $1.87

29 avr. 2025, 06:00 UTC

Résultats

AstraZeneca PLC 1Q Rev $13.59B

29 avr. 2025, 06:00 UTC

Résultats

AstraZeneca PLC 1Q Oper Pft $3.67B

29 avr. 2025, 06:00 UTC

Résultats

AstraZeneca PLC 1Q Pretax Pft $3.4B

15 avr. 2025, 09:55 UTC

Market Talk

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

9 avr. 2025, 07:23 UTC

Market Talk

Pharma Stocks Tumble After Trump Floats Tariffs on Industry -- Market Talk

3 avr. 2025, 08:41 UTC

Market Talk

Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

3 avr. 2025, 08:36 UTC

Market Talk

U.K. Pharma to Have Some Share-Price Volatility But Long-Term Outlook Remains Intact -- Market Talk

3 avr. 2025, 07:51 UTC

Market Talk

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

31 mars 2025, 09:31 UTC

Actions en Tendance

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

Comparaison

Variation de prix

AstraZeneca PLC ADR prévision

Objectif de Prix

By TipRanks

20.44% hausse

Prévisions sur 12 Mois

Moyen 87.14 USD  20.44%

Haut 97 USD

Bas 75 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

7 ratings

7

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

N/A / 69.55Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Strong Bearish Evidence

Long Terme

Weak Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos AstraZeneca PLC ADR

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.